David J Brooks

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8427021/publications.pdf

Version: 2024-02-01

339 papers	46,405 citations	1799 103 h-index	2033 205 g-index
373 all docs	373 docs citations	373 times ranked	35526 citing authors

#	Article	IF	Citations
1	Neuroinflammation in Alzheimer's disease. Lancet Neurology, The, 2015, 14, 388-405.	10.2	4,129
2	A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa. New England Journal of Medicine, 2000, 342, 1484-1491.	27.0	1,467
3	The Parkinson Progression Marker Initiative (PPMI). Progress in Neurobiology, 2011, 95, 629-635.	5.7	1,278
4	Direct brain infusion of glial cell lineâ€“derived neurotrophic factor in Parkinson disease. Nature Medicine, 2003, 9, 589-595.	30.7	1,244
5	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	7.4	1,166
6	Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Human Brain Mapping, 2003, 19, 224-247.	3.6	1,040
7	In-vivo measurement of activated microglia in dementia. Lancet, The, 2001, 358, 461-467.	13.7	983
8	In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiology of Disease, 2006, 21, 404-412.	4.4	982
9	Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain, 2005, 128, 1314-1322.	7.6	905
10	Randomized controlled trial of intraputamenal glial cell lineâ€“derived neurotrophic factor infusion in Parkinson disease. Annals of Neurology, 2006, 59, 459-466.	5.3	890
11	Core assessment program for intracerebral transplantations (CAPIT). Movement Disorders, 1992, 7, 2-13.	3.9	874
12	Slower progression of Parkinson's disease with ropinirole versus levodopa: The REALâ€PET study. Annals of Neurology, 2003, 54, 93-101.	5.3	820
13	Inflammation after trauma: Microglial activation and traumatic brain injury. Annals of Neurology, 2011, 70, 374-383.	5.3	803
14	11C-PiB PET assessment of change in fibrillar amyloid-Î² load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurology, The, 2010, 9, 363-372.	10.2	674
15	Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nature Neuroscience, 1999, 2, 1137-1140.	14.8	663
16	¹⁸Fâ€flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Annals of Neurology, 2010, 68, 319-329.	5.3	582
17	Prevalence of Amyloid PET Positivity in Dementia Syndromes. JAMA - Journal of the American Medical Association, 2015, 313, 1939.	7.4	501
18	Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiology of Disease, 2008, 32, 412-419.	4.4	448

#	Article	IF	Citations
19	Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Annals of Neurology, 2006, 59, 852-858.	5.3	435
20	Dyskinesias following neural transplantation in Parkinson's disease. Nature Neuroscience, 2002, 5, 627-628.	14.8	424
21	Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Annals of Neurology, 1994, 35, 172-180.	5.3	412
22	Brain-first versus body-first Parkinsonâ€™s disease: a multimodalÂimaging case-control study. Brain, 2020, 143, 3077-3088.	7.6	398
23	Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurology, The, 2012, 11, 241-249.	10.2	390
24	Microglial activation in presymptomatic Huntington's disease gene carriers. Brain, 2007, 130, 1759-1766.	7.6	385
25	Mapping the network for planning: a correlational PET activation study with the Tower of London task. Brain, 1999, 122, 1973-1987.	7.6	368
26	Characterizing mild cognitive impairment in incident Parkinson disease. Neurology, 2014, 82, 308-316.	1.1	359
27	Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab. Archives of Neurology, 2012, 69, 198.	4.5	349
28	The spectrum of nonmotor symptoms in early Parkinson disease. Neurology, 2013, 80, 276-281.	1.1	349
29	Identification of the Cerebral Loci Processing Human Swallowing With H₂¹⁵O PET Activation. Journal of Neurophysiology, 1999, 81, 1917-1926.	1.8	338
30	Validation of the freezing of gait questionnaire in patients with Parkinson's disease. Movement Disorders, 2009, 24, 655-661.	3.9	332
31	Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Annals of Neurology, 1997, 42, 95-107.	5.3	331
32	Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain, 2005, 128, 2786-2796.	7.6	315
33	The role of inheritance in sporadic Parkinson's disease: Evidence from a longitudinal study of dopaminergic function in twins. Annals of Neurology, 1999, 45, 577-582.	5.3	306
34	Transplantation of fetal dopamine neurons in Parkinson's disease: PET {18F}6-L-fluorodopa studies in two patients with putaminal implants. Annals of Neurology, 1992, 31, 166-173.	5.3	304
35	Increased dopamine tone during meditation-induced change of consciousness. Cognitive Brain Research, 2002, 13, 255-259.	3.0	300
36	Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid Î²-Amyloid 42. JAMA Neurology, 2014, 71, 1282.	9.0	300

#	Article	IF	Citations
37	Healthâ€related quality of life in early Parkinson's disease: The impact of nonmotor symptoms. Movement Disorders, 2014, 29, 195-202.	3.9	292
38	The Human Premotor Cortex Is 'Mirror' Only for Biological Actions. Current Biology, 2004, 14, 117-120.	3.9	285
39	Association of abnormal cerebellar activation with motor learning difficulties in dyslexic adults. Lancet, The, 1999, 353, 1662-1667.	13.7	277
40	Phase 1 Study of the Pittsburgh Compound B Derivative ¹⁸F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease. Journal of Nuclear Medicine, 2009, 50, 1251-1259.	5.0	273
41	Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. Brain, 2010, 133, 3434-3443.	7.6	273
42	Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinsonâ€™s Patients with Neural Transplants. Science Translational Medicine, 2010, 2, 38ra46.	12.4	272
43	Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study. Movement Disorders, 1998, 13, 39-45.	3.9	262
44	Glial cell lineâ€“derived neurotrophic factor induces neuronal sprouting in human brain. Nature Medicine, 2005, 11, 703-704.	30.7	256
45	Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. Lancet Neurology, The, 2020, 19, 951-962.	10.2	254
46	Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. Brain, 2008, 131, 1294-1302.	7.6	247
47	Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Annals of Neurology, 2000, 48, 689-695.	5.3	246
48	Age at onset and Parkinson disease phenotype. Neurology, 2016, 86, 1400-1407.	1.1	245
49	An early and late peak in microglial activation in Alzheimerâ€™s disease trajectory. Brain, 2017, 140, aww349.	7.6	245
50	Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain, 2005, 128, 2977-2986.	7.6	241
51	In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. Lancet Neurology, The, 2018, 17, 618-628.	10.2	228
52	Staging of serotonergic dysfunction in Parkinson's Disease: An in vivo 11C-DASB PET study. Neurobiology of Disease, 2010, 40, 216-221.	4.4	213
53	Gender-related differences in the burden of non-motor symptoms in Parkinsonâ€™s disease. Journal of Neurology, 2012, 259, 1639-1647.	3.6	211
54	Imaging markers for Alzheimer disease. Neurology, 2013, 81, 487-500.	1.1	204

#	Article	IF	Citations
55	Microglia, Amyloid, and Glucose Metabolism in Parkinsonâ€™s Disease with and without Dementia. Neuropsychopharmacology, 2013, 38, 938-949.	5.4	202
56	Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinsonâ€™s disease patients. Journal of Clinical Investigation, 2014, 124, 1340-1349.	8.2	202
57	Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain, 2003, 126, 1127-1135.	7.6	201
58	Whole-Body Biodistribution and Radiation Dosimetry of ¹⁸F-GE067: A Radioligand for In Vivo Brain Amyloid Imaging. Journal of Nuclear Medicine, 2009, 50, 818-822.	5.0	200
59	Quantitation of Carbon-11-labeled raclopride in rat striatum using positron emission tomography. Synapse, 1992, 12, 47-54.	1.2	198
60	Huntington's disease progression. Brain, 1999, 122, 2353-2363.	7.6	193
61	Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: An18F-dopa PET study. Annals of Neurology, 2002, 52, 849-853.	5.3	192
62	Baseline and longitudinal grey matter changes in newly diagnosed Parkinsonâ€™s disease: ICICLE-PD study. Brain, 2015, 138, 2974-2986.	7.6	188
63	Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: A multimodal imaging study. Human Brain Mapping, 2011, 32, 258-270.	3.6	181
64	Amyloid load and cerebral atrophy in Alzheimer's disease: An ¹¹Câ€PIB positron emission tomography study. Annals of Neurology, 2006, 60, 145-147.	5.3	178
65	Imaging Approaches to Parkinson Disease. Journal of Nuclear Medicine, 2010, 51, 596-609.	5.0	178
66	Glutamate NMDA receptor dysregulation in Parkinsonâ€™s disease with dyskinesias. Brain, 2011, 134, 979-986.	7.6	177
67	A European multicentre PET study of fibrillar amyloid in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 104-114.	6.4	170
68	Minocycline 1â€year therapy in multipleâ€systemâ€atrophy: Effect on clinical symptoms and [¹¹C] (R)â€PK11195 PET (MEMSAâ€trial). Movement Disorders, 2010, 25, 97-107.	3.9	163
69	In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy. Movement Disorders, 2006, 21, 89-93.	3.9	162
70	Influence of microglial activation on neuronal function in Alzheimer's and Parkinson's disease dementia. Alzheimer's and Dementia, 2015, 11, 608.	0.8	161
71	Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. Lancet Neurology, The, 2017, 16, 789-796.	10.2	155
72	Plasticity of the nigropallidal pathway in Parkinson's disease. Annals of Neurology, 2003, 53, 206-213.	5.3	152

#	Article	IF	Citations
73	Imaging biomarkers in Parkinson's disease. Progress in Neurobiology, 2011, 95, 614-628.	5.7	151
74	Graftâ€induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. Movement Disorders, 2011, 26, 1997-2003.	3.9	151
75	Endogenous dopamine release after pharmacological challenges in Parkinson's disease. Annals of Neurology, 2003, 53, 647-653.	5.3	149
76	Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimerâ€™s disease. Brain, 2017, 140, 2002-2011.	7.6	147
77	Development of dyskinesias in a 5â€year trial of ropinirole and <scp>L</scp>â€dopa. Movement Disorders, 2006, 21, 1844-1850.	3.9	145
78	Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. Movement Disorders, 2009, 24, 949-964.	3.9	145
79	Impaired recognition of facial expressions of anger in Parkinson's disease patients acutely withdrawn from dopamine replacement therapy. Neuropsychologia, 2007, 45, 65-74.	1.6	143
80	Microglial activation correlates in vivo with both tau and amyloid in Alzheimerâ€™s disease. Brain, 2018, 141, 2740-2754.	7.6	143
81	Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain, 2002, 125, 2248-2256.	7.6	141
82	The role of opioids in restless legs syndrome: an [11C]diprenorphine PET study. Brain, 2005, 128, 906-917.	7.6	140
83	Imaging in Parkinsonâ€™s Disease: The Role of Monoamines in Behavior. Biological Psychiatry, 2006, 59, 908-918.	1.3	136
84	Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study. Movement Disorders, 1998, 13, 46-51.	3.9	135
85	Imaging acetylcholinesterase density in peripheral organs in Parkinson's disease with 11C-donepezil PET. Brain, 2015, 138, 653-663.	7.6	135
86	Evaluation of the noradrenergic system in Parkinsonâ€™s disease: an 11C-MeNER PET and neuromelanin MRI study. Brain, 2018, 141, 496-504.	7.6	135
87	EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1885-1912.	6.4	134
88	Association of Cerebral Amyloid-Î² Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	11.0	133
89	In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration. Movement Disorders, 2004, 19, 1221-1226.	3.9	128
90	Increased microglia activation in neurologically asymptomatic HIV-infected patients receiving effective ART. Aids, 2014, 28, 67-72.	2.2	128

#	Article	IF	Citations
91	Genetic impact on cognition and brain function in newly diagnosed Parkinsonâ€™s disease: ICICLE-PD study. Brain, 2014, 137, 2743-2758.	7.6	127
92	Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimerâ€™s disease: study protocol for a randomised controlled trial (ELAD study). Trials, 2019, 20, 191.	1.6	127
93	Imaging microglial activation in Huntington's disease. Brain Research Bulletin, 2007, 72, 148-151.	3.0	122
94	GABAergic Dysfunction in Essential Tremor: An¹¹C-Flumazenil PET Study. Journal of Nuclear Medicine, 2010, 51, 1030-1035.	5.0	122
95	The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimerâ€™s disease: a longitudinal PET study. Journal of Neuroinflammation, 2020, 17, 151.	7.2	122
96	Progression of monoaminergic dysfunction in Parkinson's disease: A longitudinal 18F-dopa PET study. NeuroImage, 2011, 56, 1463-1468.	4.2	119
97	Amyloid pathology and axonal injury after brain trauma. Neurology, 2016, 86, 821-828.	1.1	116
98	In vivoimaging of neuromelanin in Parkinsonâ€™s disease using¹⁸F-AV-1451 PET. Brain, 2016, 139, 2039-2049.	7.6	113
99	Extrastriatal monoamine neuron function in Parkinsonâ€™s disease: An 18F-dopa PET study. Neurobiology of Disease, 2008, 29, 381-390.	4.4	111
100	Prefrontal cortex activity in people with schizophrenia and control subjects. British Journal of Psychiatry, 1998, 172, 316-323.	2.8	110
101	Imaging neurodegeneration in Parkinson's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 722-729.	3.8	110
102	Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [¹⁸F]FDGâ€PET. Movement Disorders, 2001, 16, 1014-1022.	3.9	109
103	Dopamine agonists and neuroprotection in parkinson's disease. Annals of Neurology, 1998, 44, S167-74.	5.3	108
104	Serotonin Neuron Loss and Nonmotor Symptoms Continue in Parkinsonâ€™s Patients Treated with Dopamine Grafts. Science Translational Medicine, 2012, 4, 128ra41.	12.4	107
105	Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain, 2004, 127, 1332-1342.	7.6	104
106	Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimerâ€™s disease. Brain, 2015, 138, 3685-3698.	7.6	102
107	Upregulation of opioid receptor binding following spontaneous epileptic seizures. Brain, 2007, 130, 1009-1016.	7.6	101
108	Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: An in vivo 11C-raclopride PET study. Experimental Neurology, 2008, 214, 112-116.	4.1	101

#	Article	IF	Citations
109	18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse, 2002, 43, 201-207.	1.2	100
110	Increased activation of frontal areas during arm movement in idiopathic torsion dystonia. Movement Disorders, 1998, 13, 309-318.	3.9	97
111	Positron emission tomography and single-photon emission computed tomography in central nervous system drug development. NeuroRx, 2005, 2, 226-236.	6.0	97
112	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	9.0	97
113	Temporally-specific retrograde amnesia in two cases of discrete bilateral hippocampal pathology. Hippocampus, 1999, 9, 247-254.	1.9	96
114	Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD. Neurology, 2013, 80, 1850-1855.	1.1	95
115	A Proposal for a Comprehensive Grading of Parkinson's Disease Severity Combining Motor and Non-Motor Assessments: Meeting an Unmet Need. PLoS ONE, 2013, 8, e57221.	2.5	95
116	Volumes, spatial extents and a probabilistic atlas of the human basal ganglia and thalamus. NeuroImage, 2007, 38, 261-270.	4.2	94
117	Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective. Neuropsychiatric Disease and Treatment, 2008, 4, 39.	2.2	93
118	Flutriciclamide (¹⁸F-GE180) PET: First-in-Human PET Study of Novel Third-Generation In Vivo Marker of Human Translocator Protein. Journal of Nuclear Medicine, 2016, 57, 1753-1759.	5.0	93
119	Effect of Lâ€dopa and 6â€hydroxydopamine lesioning on [¹¹C]raclopride binding in rat striatum, quantified using PET. Synapse, 1995, 21, 45-53.	1.2	91
120	Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study. Brain, 2003, 126, 312-325.	7.6	90
121	Motor and <scp>N</scp>onmotor <scp>C</scp>omplications of <scp>L</scp>evodopa: <scp>P</scp>henomenology, <scp>R</scp>isk <scp>F</scp>actors, and <scp>I</scp>maging <scp>F</scp>eatures. Movement Disorders, 2018, 33, 909-919.	3.9	89
122	Carotid body autotransplantation in Parkinson disease: a clinical and positron emission tomography study. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 825-831.	1.9	88
123	Implementation and application of a brain template for multiple volumes of interest. Human Brain Mapping, 2002, 15, 165-174.	3.6	87
124	Grey and white matter flumazenil binding in neocortical epilepsy with normal MRI. A PET study of 44 patients. Brain, 2003, 126, 1300-1318.	7.6	87
125	Quantitative Measurement of Bloodâ€"Brain Barrier Permeability Using Rubidium-82 and Positron Emission Tomography. Journal of Cerebral Blood Flow and Metabolism, 1984, 4, 535-545.	4.3	86
126	Monoamine neuron innervation of the normal human brain: an 18F-DOPA PET study. Brain Research, 2003, 982, 137-145.	2.2	84

#	Article	IF	Citations
127	Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography. Movement Disorders, 2009, 24, S742-7.	3.9	84
128	The effect of movement frequency on cerebral activation: a positron emission tomography study. Journal of the Neurological Sciences, 1997, 151, 195-205.	0.6	83
129	Neuroimaging in Parkinsonâ€™s disease. NeuroRx, 2004, 1, 243-254.	6.0	82
130	Novel Reference Region Model Reveals Increased Microglial and Reduced Vascular Binding of ¹¹C-(R)-PK11195 in Patients with Alzheimer's Disease. Journal of Nuclear Medicine, 2008, 49, 1249-1256.	5.0	81
131	The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 657-665.	1.9	80
132	Central Benzodiazepine/gamma-Aminobutyric AcidA Receptors in Idiopathic Generalized Epilepsy: An [11C]Flumazenil Positron Emission Tomography Study. Epilepsia, 1997, 38, 1089-1097.	5.1	79
133	Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. Brain, 2011, 134, 293-300.	7.6	79
134	Parkinson's Disease â€“ the Debate on the Clinical Phenomenology, Aetiology, Pathology and Pathogenesis. Journal of Parkinson's Disease, 2013, 3, 1-11.	2.8	79
135	Molecular imaging of dopamine transporters. Ageing Research Reviews, 2016, 30, 114-121.	10.9	79
136	Decreased intestinal acetylcholinesterase in early Parkinson disease. Neurology, 2017, 88, 775-781.	1.1	75
137	A Two-Compartment Description and Kinetic Procedure for Measuring Regional Cerebral [¹¹C]Nomifensine Uptake Using Positron Emission Tomography. Journal of Cerebral Blood Flow and Metabolism, 1990, 10, 307-316.	4.3	73
138	11C-Diprenorphine Binding in Huntington's Disease: A Comparison of Region of Interest Analysis with Statistical Parametric Mapping. Journal of Cerebral Blood Flow and Metabolism, 1997, 17, 943-949.	4.3	73
139	Correlates of local cerebral blood flow (CBF) in normal pressure hydrocephalus patients before and after shuntingâ€”A retrospective analysis of [15O]H2O PET-CBF studies in 65 patients. Clinical Neurology and Neurosurgery, 2008, 110, 369-375.	1.4	70
140	Kinetic analysis of the translocator protein positron emission tomography ligand [18F]GE-180 in the human brain. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2201-2210.	6.4	70
141	In vivo [11C] flumazenil-PET correlates with ex vivo [3H] flumazenil autoradiography in hippocampal sclerosis. Annals of Neurology, 1998, 43, 618-626.	5.3	69
142	Microglial activation in early Alzheimer trajectory is associated with higher gray matter volume. Neurology, 2019, 92, e1331-e1343.	1.1	69
143	Brain opioid receptor binding in early abstinence from opioid dependence. British Journal of Psychiatry, 2007, 191, 63-69.	2.8	68
144	Initial Evaluation of 18F-GE-179, a Putative PET Tracer for Activated N-Methyl d-Aspartate Receptors. Journal of Nuclear Medicine, 2014, 55, 423-430.	5.0	68

#	Article	IF	Citations
145	STN Stimulation Alters Pallidalâ€"Frontal Coupling during Response Selection under Competition. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 1173-1184.	4.3	67
146	Using [11C]Diprenorphine to Image Opioid Receptor Occupancy by Methadone in Opioid Addiction: Clinical and Preclinical Studies. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 309-315.	2.5	66
147	Imaging neuroinflammation in Alzheimer's disease and other dementias: Recent advances and future directions. Alzheimer's and Dementia, 2015, 11, 1110-1120.	0.8	66
148	Brain dopamine response in human opioid addiction. British Journal of Psychiatry, 2008, 193, 65-72.	2.8	64
149	Dynamic ¹¹C-PiB PET Shows Cerebrospinal Fluid Flow Alterations in Alzheimer Disease and Multiple Sclerosis. Journal of Nuclear Medicine, 2019, 60, 1452-1460.	5.0	64
150	Stereotactic thalamotomy in tremorâ€dominant Parkinson's disease: An H₂¹⁵O PET motor activation study. Annals of Neurology, 1997, 41, 108-111.	5.3	62
151	Does Microglial Activation Influence Hippocampal Volume and Neuronal Function in Alzheimerâ€™s Disease and Parkinsonâ€™s Disease Dementia?. Journal of Alzheimer's Disease, 2016, 51, 1275-1289.	2.6	62
152	Brain opioid receptor binding in early abstinence from alcohol dependence and relationship to craving: An [11C]diprenorphine PET study. European Neuropsychopharmacology, 2009, 19, 740-748.	0.7	61
153	What can biomarkers tell us about cognition in Parkinson's disease?. Movement Disorders, 2014, 29, 622-633.	3.9	61
154	Thalamic inflammation after brain trauma is associated with thalamo-cortical white matter damage. Journal of Neuroinflammation, 2015, 12, 224.	7.2	60
155	Hypothalamic volume loss is associated with reduced melatonin output in Parkinson's disease. Movement Disorders, 2016, 31, 1062-1066.	3.9	59
156	Measurement of Regional Cerebral pH in Human Subjects Using Continuous Inhalation of 11CO2 and Positron Emission Tomography. Journal of Cerebral Blood Flow and Metabolism, 1984, 4, 458-465.	4.3	58
157	Statistical neuroanatomy of the human inferior frontal gyrus and probabilistic atlas in a standard stereotaxic space. Human Brain Mapping, 2007, 28, 34-48.	3.6	58
158	Prevalence of the apolipoprotein E Îµ4 allele in amyloid Î² positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.8	58
159	Safety and tolerability of COMT inhibitors. Neurology, 2004, 62, S39-46.	1.1	58
160	The Effect of the Nitric Oxide Synthase Inhibitor L-NMMA on Basal CBF and Vasoneuronal Coupling in Man: A PET Study. Journal of Cerebral Blood Flow and Metabolism, 1999, 19, 673-678.	4.3	57
161	Regional locus coeruleus degeneration is uncoupled from noradrenergic terminal loss in Parkinsonâ€™s disease. Brain, 2021, 144, 2732-2744.	7.6	57
162	Neuronal loss associated with cognitive performance in amyotrophic lateral sclerosis: An (¹¹C)â€flumazenil PET study. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 43-49.	2.1	56

#	Article	IF	Citations
163	Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers. Neurobiology of Disease, 2010, 37, 356-361.	4.4	56
164	The catechol-O-methyltransferase Val158Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinsonâ€™s disease: a PET study. Brain, 2012, 135, 2449-2457.	7.6	56
165	Binary classification of 18F-flutemetamol PET using machine learning: Comparison with visual reads and structural MRI. NeuroImage, 2013, 64, 517-525.	4.2	56
166	Cerebral glucose metabolism in corticobasal degeneration: Comparison with progressive supranuclear palsy and normal controls. Movement Disorders, 1997, 12, 691-696.	3.9	55
167	An Open-Label, Positron Emission Tomography Study to Assess Adenosine A2A Brain Receptor Occupancy of Vipadenant (BIIB014) at Steady-State Levels in Healthy Male Volunteers. Clinical Neuropharmacology, 2010, 33, 55-60.	0.7	55
168	AÎ² Imaging: feasible, pertinent, and vital to progress in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 209-219.	6.4	55
169	Lâ€Dihydroxyphenylalanine and its decarboxylase: New ideas on their neuroregulatory roles. Movement Disorders, 1995, 10, 241-249.	3.9	52
170	Combination of Biomarkers: PET [¹⁸F]Flutemetamol Imaging and Structural MRI in Dementia and Mild Cognitive Impairment. Neurodegenerative Diseases, 2012, 10, 246-249.	1.4	52
171	[123I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB1 receptors before and after Î”9-tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in tourette patients. Biological Psychiatry, 2004, 55, 904-915.	1.3	51
172	Benefits of putaminal GDNF infusion in Parkinson disease are maintained after GDNF cessation. Neurology, 2013, 81, 1176-1178.	1.1	51
173	A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson's disease. Metabolic Brain Disease, 1999, 14, 45-55.	2.9	50
174	Imaging end points for monitoring neuroprotection in Parkinson's disease. Annals of Neurology, 2003, 53, S110-S119.	5.3	49
175	Parkinson's disease: Diagnosis. Parkinsonism and Related Disorders, 2012, 18, S31-S33.	2.2	49
176	Intraâ€•and interâ€•network functional alterations in <scp>P</scp>arkinson's disease with mild cognitive impairment. Human Brain Mapping, 2017, 38, 1702-1715.	3.6	49
177	Brain Microglial Activation Increased in Glucocerebrosidase (<scp>GBA</scp>) Mutation Carriers without Parkinson's disease. Movement Disorders, 2021, 36, 774-779.	3.9	49
178	Nigrostriatal function in vitamin E deficiency: Clinical, experimental, and positron emission tomographic studies. Annals of Neurology, 1994, 35, 298-303.	5.3	48
179	Genetic linkage of autosomal dominant progressive supranuclear palsy to 1q31.1. Annals of Neurology, 2005, 57, 634-641.	5.3	48
180	Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease. Neurobiology of Aging, 2017, 55, 78-90.	3.1	48

#	Article	IF	Citations
181	Benzodiazepine-GABAA Receptors in Idiopathic Generalized Epilepsy Measured with [11C]Flumazenil and Positron Emission Tomography. Epilepsia, 1995, 36, 113-121.	5.1	47
182	Health-related quality of life following bilateral intrastriatal transplantation in Parkinson's disease. Movement Disorders, 2000, 15, 224-229.	3.9	47
183	A [¹¹C]Ro15 4513 PET study suggests that alcohol dependence in man is associated with reduced Î±5 benzodiazepine receptors in limbic regions. Journal of Psychopharmacology, 2012, 26, 273-281.	4.0	47
184	In Vivo cortical tau in Parkinson's disease using 18F-AV-1451 positron emission tomography. Movement Disorders, 2017, 32, 922-927.	3.9	47
185	Balancing bias, reliability, noise properties and the need for parametric maps in quantitative ligand PET: [11C]diprenorphine testâ€“retest data. NeuroImage, 2007, 38, 82-94.	4.2	46
186	Does inflammation precede tau aggregation in early Alzheimer's disease? A PET study. Neurobiology of Disease, 2018, 117, 211-216.	4.4	46
187	Volumetric cortical loss in sporadic and familial amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 343-347.	2.1	45
188	MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([18F]-AV-1451) Binding. Molecular Imaging and Biology, 2018, 20, 356-360.	2.6	45
189	Reward Processing in Health and Parkinson's Disease: Neural Organization and Reorganization. Cerebral Cortex, 2004, 14, 73-80.	2.9	44
190	Nigrostriatal dysfunction in homozygous and heterozygous parkin gene carriers: An ¹⁸Fâ€dopa PET progression study. Movement Disorders, 2009, 24, 2260-2266.	3.9	44
191	Depression in ParkinsonÊ¼s disease. Current Opinion in Neurology, 2001, 14, 465-470.	3.6	43
192	DIAGNOSIS AND MANAGEMENT OF ATYPICAL PARKINSONIAN SYNDROMES. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, i10-i16.	1.9	43
193	Cortical involvement in four cases of primary lateral sclerosis using [11C]-flumazenil PET. Journal of Neurology, 2007, 254, 1033-1036.	3.6	42
194	The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study. Neurobiology of Aging, 2015, 36, 1736-1742.	3.1	42
195	The Cholinergic Brain in Parkinson's Disease. Movement Disorders Clinical Practice, 2021, 8, 1012-1026.	1.5	42
196	Widespread microglial activation in multiple system atrophy. Movement Disorders, 2019, 34, 564-568.	3.9	41
197	Advances in the understanding of early Huntington's disease using the functional imaging techniques of PET and SPET. Trends in Molecular Medicine, 1998, 4, 532-539.	2.6	40
198	Serotonergic mediated body mass index changes in Parkinson's disease. Neurobiology of Disease, 2011, 43, 609-615.	4.4	40

#	Article	IF	Citations
199	In Vivo Imaging of Human Acetylcholinesterase Density in Peripheral Organs Using ¹¹C-Donepezil: Dosimetry, Biodistribution, and Kinetic Analyses. Journal of Nuclear Medicine, 2014, 55, 1818-1824.	5.0	40
200	Reduced Synaptic Density in Patients with Lewy Body Dementia: An [<scp>¹¹C</scp>]<scp>UCBâ€‐J PET</scp> Imaging Study. Movement Disorders, 2021, 36, 2057-2065.	3.9	39
201	Apathy blunts neural response to money in Parkinson's disease. Social Neuroscience, 2011, 6, 653-662.	1.3	38
202	[11C]Flumazenil PET in Temporal Lobe Epilepsy: Do We Need an Arterial Input Function or Kinetic Modeling?. Journal of Cerebral Blood Flow and Metabolism, 2008, 28, 207-216.	4.3	37
203	Parkinsonism associated with acute intracranial hematomas: An [18F]dopa positron-emission tomography study. Movement Disorders, 1997, 12, 1035-1038.	3.9	36
204	A systematic comparison of kinetic modelling methods generating parametric maps for [11C]-(R)-PK11195. NeuroImage, 2007, 36, 28-37.	4.2	36
205	Imaging Non-Dopaminergic Function in Parkinsonâ€™s Disease. Molecular Imaging and Biology, 2007, 9, 217-222.	2.6	36
206	PET imaging reveals early and progressive dopaminergic deficits after intra-striatal injection of preformed alpha-synuclein fibrils in rats. Neurobiology of Disease, 2021, 149, 105229.	4.4	36
207	Chorea associated with thyroxine replacement therapy. Movement Disorders, 2005, 20, 1656-1657.	3.9	35
208	GDNF in treatment of Parkinson's disease: response to editorial. Lancet Neurology, The, 2006, 5, 200-202.	10.2	35
209	Longitudinal diffusion tensor imaging changes in early Parkinsonâ€™s disease: ICICLE-PD study. Journal of Neurology, 2018, 265, 1528-1539.	3.6	35
210	Extrastriatal monoaminergic dysfunction and enhanced microglial activation in idiopathic rapid eye movement sleep behaviour disorder. Neurobiology of Disease, 2018, 115, 9-16.	4.4	35
211	Monocyte markers correlate with immune and neuronal brain changes in REM sleep behavior disorder. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	35
212	Periventricular White Matter Flumazenil Binding and Postoperative Outcome in Hippocampal Sclerosis. Epilepsia, 2005, 46, 944-948.	5.1	34
213	PET Studies on the Function of Dopamine in Health and Parkinson's Disease. Annals of the New York Academy of Sciences, 2003, 991, 22-35.	3.8	34
214	Upregulation of dopamine D₂ receptors in dopaminergic drugâ€naive patients with parkin gene mutations. Movement Disorders, 2006, 21, 783-788.	3.9	34
215	New developments of brain imaging for Parkinson's disease and related disorders. Movement Disorders, 2006, 21, 2035-2041.	3.9	34
216	Technology Insight: imaging neurodegeneration in Parkinson's disease. Nature Clinical Practice Neurology, 2008, 4, 267-277.	2.5	34

#	Article	IF	Citations
217	Brain monoamine systems in multiple system atrophy: A positron emission tomography study. Neurobiology of Disease, 2012, 46, 130-136.	4.4	34
218	Asymmetric Dopaminergic Dysfunction in Brain-First versus Body-First Parkinsonâ€™s Disease Subtypes. Journal of Parkinson's Disease, 2021, 11, 1677-1687.	2.8	34
219	Imaging dopamine transporters in Parkinsonâ€™s disease. Biomarkers in Medicine, 2010, 4, 651-660.	1.4	33
220	Characterisation of the Contribution of the GABA-Benzodiazepine Î±1 Receptor Subtype to [¹¹C]Ro15-4513 PET Images. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 731-744.	4.3	33
221	Imaging synucleinopathies. Movement Disorders, 2016, 31, 814-829.	3.9	33
222	Chronic exposure to dopamine agonists affects the integrity of striatal D 2 receptors in Parkinson's patients. NeuroImage: Clinical, 2017, 16, 455-460.	2.7	33
223	Decreased noradrenaline transporter density in the motor cortex of Parkinson's disease patients. Movement Disorders, 2018, 33, 1006-1010.	3.9	33
224	Sleep problems and hypothalamic dopamine D3 receptor availability in Parkinson disease. Neurology, 2016, 87, 2451-2456.	1.1	32
225	Role of Neuroinflammation in the Trajectory of Alzheimerâ€™s Disease and in vivo Quantification Using PET. Journal of Alzheimer's Disease, 2018, 64, S339-S351.	2.6	32
226	Confirmation of Specific Binding of the 18-kDa Translocator Protein (TSPO) Radioligand [18F]GE-180: a Blocking Study Using XBD173 in Multiple Sclerosis Normal Appearing White and Grey Matter. Molecular Imaging and Biology, 2019, 21, 935-944.	2.6	32
227	Does insulin resistance influence neurodegeneration in non-diabetic Alzheimerâ€™s subjects?. Alzheimer's Research and Therapy, 2021, 13, 47.	6.2	32
228	Cognitive and motor effects of dopaminergic medication withdrawal in Parkinsonâ€™s disease. Neuropsychologia, 2004, 42, 1917-1926.	1.6	31
229	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the <scp>Movement Disorder Society</scp> Multiple System Atrophy Study Group. Movement Disorders Clinical Practice, 2020, 7, 750-762.	1.5	31
230	Acute HCV/HIV Coinfection Is Associated with Cognitive Dysfunction and Cerebral Metabolite Disturbance, but Not Increased Microglial Cell Activation. PLoS ONE, 2012, 7, e38980.	2.5	30
231	Can Studies of Neuroinflammation in a TSPO Genetic Subgroup (HAB or MAB) Be Applied to the Entire AD Cohort?. Journal of Nuclear Medicine, 2015, 56, 707-713.	5.0	30
232	Progression of sleep disturbances in Parkinsonâ€™s disease: a 5-year longitudinal study. Journal of Neurology, 2021, 268, 312-320.	3.6	30
233	Research goals in progressive supranuclear palsy. Movement Disorders, 2000, 15, 446-458.	3.9	29
234	The prognostic value of amyloid imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1207-1219.	6.4	29

#	Article	IF	Citations
235	Benzodiazepine-GABAA Receptor Binding During Absence Seizures. Epilepsia, 1995, 36, 592-599.	5.1	28
236	Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinsonâ€™s disease. Journal of Neural Transmission, 2008, 115, 843-849.	2.8	28
237	The Effect of 40-Hz Light Therapy on Amyloid Load in Patients with Prodromal and Clinical Alzheimerâ€™s Disease. International Journal of Alzheimer's Disease, 2018, 2018, 1-5.	2.0	28
238	Nigrostriatal proteasome inhibition impairs dopamine neurotransmission and motor function in minipigs. Experimental Neurology, 2018, 303, 142-152.	4.1	27
239	Ageing and amyloidosis underlie the molecular and pathological alterations of tau in a mouse model of familial Alzheimerâ€™s disease. Scientific Reports, 2019, 9, 15758.	3.3	27
240	Altered sensorimotor cortex noradrenergic function in idiopathic REM sleep behaviour disorder â€“ A PET study. Parkinsonism and Related Disorders, 2020, 75, 63-69.	2.2	27
241	Imaging basal ganglia function. Journal of Anatomy, 2000, 196, 543-554.	1.5	25
242	Updated guidelines for the management of Parkinson's disease. British Journal of Hospital Medicine, 2001, 62, 456-470.	0.2	25
243	Examining Braak's hypothesis by imaging Parkinson's disease. Movement Disorders, 2010, 25, S83-8.	3.9	25
244	In vivo assessment of brain monoamine systems in parkin gene carriers: A PET study. Experimental Neurology, 2010, 222, 120-124.	4.1	25
245	Imaging non-motor aspects of Parkinsonâ€™s disease. Progress in Brain Research, 2010, 184, 205-218.	1.4	25
246	Persistent Nigrostriatal Dopaminergic Abnormalities in Ex-Users of MDMA (â€˜Ecstasyâ€™): An 18F-Dopa PET Study. Neuropsychopharmacology, 2011, 36, 735-743.	5.4	25
247	Investigating expectation and reward in human opioid addiction with [¹¹ <scp>C</scp>]raclopride <scp>PET</scp>. Addiction Biology, 2014, 19, 1032-1040.	2.6	24
248	Strategies for the generation of parametric images of [11C]PIB with plasma input functions considering discriminations and reproducibility. NeuroImage, 2009, 48, 329-338.	4.2	23
249	Imaging Systemic Dysfunction in Parkinsonâ€™s Disease. Current Neurology and Neuroscience Reports, 2016, 16, 51.	4.2	23
250	Imaging biomarkers in tauopathies. Parkinsonism and Related Disorders, 2016, 22, S26-S28.	2.2	23
251	The Future of Brain Imaging in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2018, 8, S47-S51.	2.8	23
252	Assessment of Parkinson's disease with imaging. Parkinsonism and Related Disorders, 2007, 13, S268-S275.	2.2	22

#	Article	IF	Citations
253	Parametric mapping using spectral analysis for 11C-PBR28 PET reveals neuroinflammation in mild cognitive impairment subjects. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1432-1441.	6.4	22
254	Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 3.	6.2	22
255	In vivo imaging of synaptic SV2A protein density in healthy and striatal-lesioned rats with [11C]UCB-J PET. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 819-830.	4.3	22
256	Reference Region Automatic Extraction in Dynamic [¹¹C]PIB. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 1725-1731.	4.3	20
257	Positron emission tomography imaging of transplant function. NeuroRx, 2004, 1, 482-491.	6.0	19
258	Ventral striatal dopamine synthesis capacity is associated with individual differences in behavioral disinhibition. Frontiers in Behavioral Neuroscience, 2014, 8, 86.	2.0	19
259	Imaging Parkinsonâ€™s disease below the neck. Npj Parkinson's Disease, 2017, 3, 15.	5.3	19
260	Dopaminergic action beyond its effects on motor function: Imaging studies. Journal of Neurology, 2006, 253, iv8-iv15.	3.6	18
261	Nigral degeneration and striatal dopaminergic dysfunction in idiopathic andparkin-linked Parkinson's disease. Movement Disorders, 2006, 21, 299-305.	3.9	18
262	Diffusion-weighted imaging and its relationship to microglial activation in parkinsonian syndromes. Parkinsonism and Related Disorders, 2013, 19, 527-532.	2.2	18
263	Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson's disease patients. Movement Disorders, 2017, 32, 235-240.	3.9	18
264	Impaired perfusion and capillary dysfunction in prodromal Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12032.	2.4	18
265	Imaging dopamine function and microglia in asymptomatic LRRK2 mutation carriers. Journal of Neurology, 2020, 267, 2296-2300.	3.6	18
266	Evaluation of [11C]RTI-121 as a selective radioligand for PET studies of the dopamine transporter. Nuclear Medicine and Biology, 1996, 23, 377-384.	0.6	17
267	Opioid binding in DYT1 primary torsion dystonia: An11C-diprenorphine PET study. Movement Disorders, 2004, 19, 1498-1503.	3.9	17
268	Ventral Striatal Dopamine Synthesis Capacity Predicts Financial Extravagance in Parkinsonâ€™s Disease. Frontiers in Psychology, 2013, 4, 90.	2.1	17
269	Testâ€“retest reproducibility of cannabinoid-receptor type 1 availability quantified with the PET ligand [11C]MePPEP. NeuroImage, 2014, 97, 151-162.	4.2	17
270	Anticholinergic Load: Is there a Cognitive Cost in Early Parkinsonâ€™s Disease?. Journal of Parkinson's Disease, 2015, 5, 743-747.	2.8	17

#	Article	IF	Citations
271	The Role of Structural and Functional Imaging in Parkinsonian States with a Description of PET Technology. Seminars in Neurology, 2008, 28, 435-445.	1.4	16
272	Quantification of opioid receptor availability following spontaneous epileptic seizures: Correction of [11C]diprenorphine PET data for the partial-volume effect. NeuroImage, 2013, 79, 72-80.	4.2	16
273	An imaging study of parkinsonism among African-Caribbean and Indian London communities. Movement Disorders, 2002, 17, 1321-1328.	3.9	15
274	In vivo quantification of glial activation in minipigs overexpressing human Î±â€synuclein. Synapse, 2018, 72, e22060.	1.2	15
275	Preserved noradrenergic function in Parkinson's disease patients with rest tremor. Neurobiology of Disease, 2021, 152, 105295.	4.4	15
276	Cortical cholinergic dysfunction correlates with microglial activation in the substantia innominata in REM sleep behavior disorder. Parkinsonism and Related Disorders, 2020, 81, 89-93.	2.2	14
277	Cardiovascular effects of methamphetamine in Parkinson's disease patients. Movement Disorders, 2004, 19, 298-303.	3.9	13
278	Abnormal Amyloid Load in Mild Cognitive Impairment: The Effect of Reducing the PiBâ€PET Threshold. Journal of Neuroimaging, 2019, 29, 499-505.	2.0	13
279	Attenuation of dopamineâ€induced GABA release in problem gamblers. Brain and Behavior, 2019, 9, e01239.	2.2	13
280	NMDA receptor ion channel activation detected in vivo with [¹⁸F]GE-179 PET after electrical stimulation of rat hippocampus. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 1301-1312.	4.3	12
281	The clinical role of PET in cerebrovascular disease. Neurosurgical Review, 1991, 14, 91-96.	2.4	11
282	Clinical pharmacology and therapeutic use of COMT inhibition in Parkinson's disease. Journal of Neurology, 2007, 254, IV37-IV48.	3.6	11
283	The risk of exaggerated risk aversionâ€”a life and death struggle for molecular imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1693-1694.	6.4	11
284	Observations on muscle activity in REM sleep behavior disorder assessed with a semi-automated scoring algorithm. Clinical Neurophysiology, 2018, 129, 541-547.	1.5	11
285	Comment on â€œIn Vivo [¹⁸F]GE-179 Brain Signal Does Not Show NMDA-Specific Modulation with Drug Challenges in Rodents and Nonhuman Primatesâ€. ACS Chemical Neuroscience, 2019, 10, 768-772.	3.5	11
286	Using [11C]Ro15 4513 PET to characterise GABA-benzodiazepine receptors in opiate addiction: Similarities and differences with alcoholism. NeuroImage, 2016, 132, 1-7.	4.2	10
287	Tau Tangles in Parkinsonâ€™s Disease: A 2-Year Follow-Up Flortaucipir PET Study. Journal of Parkinson's Disease, 2020, 10, 161-171.	2.8	10
288	Positron emission tomography in the study of cerebral tumours. Neurosurgical Review, 1984, 7, 253-258.	2.4	9

#	Article	IF	Citations
289	Imaging the role of dopamine in health and disease Parkinson's disease as a lesion model. Wiener Klinische Wochenschrift, 2006, 118, 570-572.	1.9	9
290	Milestones in neuroimaging. Movement Disorders, 2011, 26, 868-978.	3.9	9
291	Can imaging separate multiple system atrophy from Parkinson's disease?. Movement Disorders, 2012, 27, 3-5.	3.9	9
292	Application of advanced brain positron emission tomographyâ€“based molecular imaging for a biological framework in neurodegenerative proteinopathies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 327-332.	2.4	9
293	Technical aspects of amyloid imaging for Alzheimer's disease. Alzheimer's Research and Therapy, 2011, 3, 25.	6.2	8
294	Resting tremor in Parkinson disease: Is the pallidum to blame?. Annals of Neurology, 2011, 69, 229-231.	5.3	8
295	11C-PiB PET does not detect PrP-amyloid in prion disease patients including variant Creutzfeldtâ€“Jakob disease: Figure 1. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 340-341.	1.9	8
296	Preclinical PET Studies of [11C]UCB-J Binding in Minipig Brain. Molecular Imaging and Biology, 2020, 22, 1290-1300.	2.6	8
297	International Medical Workshop covering progressive supranuclear palsy, multiple system atrophy and cortico basal degeneration. Movement Disorders, 2001, 16, 382-395.	3.9	6
298	Impaired cerebral microcirculation in isolated REM sleep behaviour disorder. Brain, 2021, 144, 1498-1508.	7.6	6
299	Recent imaging advances in the diagnosis and management of Parkinson's disease. F1000 Medicine Reports, 2009, 1, .	2.9	6
300	In vivo vesicular acetylcholine transporter density in human peripheral organs: an [18F]FEOBV PET/CT study. EJNMMI Research, 2022, 12, 17.	2.5	6
301	Imaging of genetic and degenerative disorders primarily causing Parkinsonism. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 135, 493-505.	1.8	5
302	Future Imaging in Dementia. Seminars in Nuclear Medicine, 2021, 51, 303-308.	4.6	5
303	Gaitâ€Related Metabolic Covariance Networks at Rest in Parkinson's Disease. Movement Disorders, 2022, 37, 1222-1234.	3.9	5
304	Chapter 14 Non-invasive in vivo imaging of transplant function. Progress in Brain Research, 2000, 127, 321-332.	1.4	4
305	Simplifying [18F]GE-179 PET: are both arterial blood sampling and 90-min acquisitions essential?. EJNMMI Research, 2018, 8, 46.	2.5	4
306	18F-GE180, a radioligand for the TSPO protein: not ready for clinical trials in multiple sclerosis. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2242-2243.	6.4	4

#	Article	IF	Citations
307	Impulse control disorders are associated with lower ventral striatum dopamine D3 receptor availability in Parkinson's disease: A [11C]-PHNO PET study. Parkinsonism and Related Disorders, 2021, 90, 52-56.	2.2	4
308	Capillary function progressively deteriorates in prodromal Alzheimerâ€™s disease: A longitudinal MRI perfusion study. Aging Brain, 2022, 2, 100035.	1.3	4
309	Imaging Familial and Sporadic Neurodegenerative Disorders Associated with Parkinsonism. Neurotherapeutics, 2021, 18, 753-771.	4.4	3
310	Activated Nâ€methylâ€Dâ€aspartate receptor ion channels detected in focal epilepsy with [¹⁸F]GEâ€179 positron emission tomography. Epilepsia, 2021, 62, 2899-2908.	5.1	3
311	Imaging studies in drug development: Parkinson's disease. Drug Discovery Today: Technologies, 2005, 2, 317-321.	4.0	2
312	In Response to Letter from Fregonara et al. 2019. Molecular Imaging and Biology, 2020, 22, 13-14.	2.6	2
313	PET Imaging of Translocator Protein Expression in Neurological Disorders. , 2021, , 1021-1040.		2
314	Towards improved test-retest reliability in quantitative ligand PET: [11C]Diprenorphine as an example. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S665-S665.	4.3	2
315	Spontaneous partial recovery of striatal dopaminergic uptake despite nigral cell loss in asymptomatic MPTP-lesioned female minipigs. NeuroToxicology, 2022, 91, 166-176.	3.0	2
316	PET: Motor function and dysfunction. Movement Disorders, 1992, 7, 20-20.	3.9	1
317	Global Increase in Cortical Opioid Binding Potential with Aging: In Vivo Quantification with 11C diprenorphine PET. Psychogeriatrics, 2001, 1, 309-316.	1.2	1
318	Imaging Parkinson's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 83, 245-263.	1.8	1
319	Bad News for Neuroprotective Therapies in PD?. Journal of Parkinson's Disease, 2013, 3, 271-273.	2.8	1
320	[P2â€“197]: AMYLOID DEPOSITION, TAU AGGREGATION AND MICROGLIAL ACTIVATION CORRELATE WITH VASCULAR BURDEN IN VIVO IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P681.	0.8	1
321	[O1â€“12â€“01]: [18F]FLUTEMETAMOL AMYLOID SCANNING IN A PHASE III AMNESTIC MILD COGNITIVE IMPAIRMENT STUDY: ADDITIONAL INFLUENCE OF OTHER BIOMARKERS IN ESTIMATING RISK OF CONVERSION TO PROBABLE ALZHEIMERS DISEASE. Alzheimer's and Dementia, 2017, 13, P221.	0.8	1
322	Temporally-specific retrograde amnesia in two cases of discrete bilateral hippocampal pathology. , 1999, 9, 247.		1
323	Correlation of regional cerebral amyloid load in Alzheimer's disease, measured with [11C]-PIB pet using spectral analysis and tissue uptake ratios, with Performance on recognition memory tests. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S591-S591.	4.3	1
324	Reply: Nigral degeneration and striatal dopaminergic dysfunction in idiopathic and parkin-linked Parkinson's disease. Movement Disorders, 2007, 22, 1522-1522.	3.9	0

#	Article	IF	Citations
325	[P1â€“130]: DIFFERENT MODELLING APPROACHES FOR TAU TRACER ¹⁸Fâ€AV1451 IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P291.	0.8	0
326	[P4â€“265]: DEEP AND FREQUENT PHENOTYPING STUDY: PET AND MR IMAGING PROTOCOL. Alzheimer's and Dementia, 2017, 13, P1385.	0.8	0
327	[ICâ€Pâ€074]: LONGITUDINAL DIFFUSION TENSOR IMAGING AS A PREDICTOR OF COGNITIVE DOMAINS DECLINE IN EARLY STAGE PARKINSON's DISEASE: ICICLEâ€PD STUDY. Alzheimer's and Dementia, 2017, 13, P61.	0.8	0
328	[ICâ€Pâ€088]: DEEP AND FREQUENT PHENOTYPING STUDY: PET AND MR IMAGING PROTOCOL. Alzheimer's and Dementia, 2017, 13, P71.	0.8	0
329	Microglial activation evaluated using flutriciclamide (11 Fâ€GE180) in subjects with cognitive impairment. Alzheimer's and Dementia, 2020, 16, e045465.	0.8	0
330	Tau formation is associated with microglial activation in more widespread cortical areas than is amyloid deposition. Alzheimer's and Dementia, 2020, 16, e046045.	0.8	0
331	Microglial Activation Is Increased in Glucocerebrosidase (GBA1) Mutation Carriers: A Cross-Sectional PET Study. SSRN Electronic Journal, 0, , .	0.4	0
332	Influence of microglial activation on structural and functional connectivity in mild cognitive impairment subjects. Alzheimer's and Dementia, 2020, 16, e042990.	0.8	0
333	Neuroimaging in Parkinsonâ€™s disease. Neurotherapeutics, 2004, 1, 243-254.	4.4	0
334	Positron emission tomography imaging of transplant function. Neurotherapeutics, 2004, 1, 482-491.	4.4	0
335	Positron emission tomography and single-photon emission computed tomography in central nervous system drug development. Neurotherapeutics, 2005, 2, 226-236.	4.4	0
336	The relationship between flutriciclamide PET uptake and grey matter atrophy in mild cognitive impairment and Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0
337	Neuroinflammation, amyloid, NFT markers and initial cognitive status predict cognitive decline in MCI patients. Alzheimer's and Dementia, 2021, 17, .	0.8	0
338	Imaging of the Parkinsonian Brain in Relation to Restorative Therapy. , 2006, , 119-130.		0
339	Neuroinflammation, functional connectivity and structural network integrity in the Alzheimer's spectrum.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e055970.	0.8	0